Therapeutic Potential of a Novel Lytic Phage, vB_EclM_ECLFM1, against Carbapenem-Resistant Enterobacter cloacae

The global rise of multidrug-resistant strains, especially those that are resistant to carbapenems and produce metallo-β-lactamases, poses a critical challenge in clinical settings owing to limited treatment options. While bacteriophages show promise in treating these infections, their use is hinder...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2024-01, Vol.25 (2), p.854
Main Authors: Ali, Saieeda Fabia, Teh, Soon-Hian, Yang, Hsueh-Hui, Tsai, Yun-Chan, Chao, Huei-Jen, Peng, Si-Shiuan, Chen, Shu-Chen, Lin, Ling-Chun, Lin, Nien-Tsung
Format: Article
Language:English
Subjects:
Animals
Antibiotics
Antimicrobial agents
Bacteria
Bacterial infections
Bacteriophages - genetics
Carbapenem-Resistant Enterobacteriaceae
Carbapenems - pharmacology
Carbapenems - therapeutic use
Drug resistance
E coli
Efficiency
Enterobacter cloacae
Genes
Morphology
Multidrug resistant organisms
Nosocomial infections
Phages
R&D
Research & development
Zebrafish
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The global rise of multidrug-resistant strains, especially those that are resistant to carbapenems and produce metallo-β-lactamases, poses a critical challenge in clinical settings owing to limited treatment options. While bacteriophages show promise in treating these infections, their use is hindered by scarce resources and insufficient genomic data. In this study, we isolated ECLFM1, a novel phage, from sewage water using a carbapenem-resistant clinical strain as the host. ECLFM1 exhibited rapid adsorption and a 15-min latent period, with a burst size of approximately 75 PFU/infected cell. Its genome, spanning 172,036 bp, was characterized and identified as a member of . In therapeutic applications, owing to a high multiplicity of infection, ECLFM1 showed increased survival in zebrafish infected with . This study highlights ECLFM1's potential as a candidate for controlling clinical infections, which would help address challenges in treating multidrug-resistant strains and contribute to the development of alternative treatments.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms25020854